BIA
RGC icon

Bell Investment Advisors’s Regencell Bioscience RGC Stock Holding History

Bell Investment Advisors’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$509 Buy
+20
New +$566 ﹤0.01% 1740

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Bell Investment Advisors's RGC Position: Q1 2026 in Review

Bell Investment Advisors opened a new position in Regencell Bioscience (RGC) in Q1 2026: 20 shares worth $509. The stake represents ﹤0.01% of the portfolio and ranks #1740 among its holdings.

31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

  • Bell Investment Advisors held 20 shares of Regencell Bioscience worth $509 as of Q1 2026.
  • Regencell Bioscience was a new Bell Investment Advisors position in Q1 2026.
  • Regencell Bioscience made up ﹤0.01% of Bell Investment Advisors's portfolio in Q1 2026, its #1740 holding.
  • 31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Bell Investment Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.